PAVmed's Subsidiary, Lucid Diagnostics Files For $58M IPO

• Lucid Diagnostic, a maker of diagnostic tests for esophageal precancer and cancer, filed to raise up to $58 million in an IPO.

• In its Form S-1 filed with SEC, the New York-based company said it intends to list on NASDAQ under the ticker symbol LUCD.

• Lucid is a wholly-owned subsidiary of medical technology firm PAVmed Inc (NASDAQ: PAVM), which owns approximately 72.6% of Lucid's common stock.

• Lucid Diagnostics markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device to detect esophageal precancer and cancer.

• The tools are used to detect gastroesophageal reflux disease, also known as chronic heartburn and acid reflux, in patients at risk of developing esophageal precancer and cancer, specifically esophageal adenocarcinoma.

• EsoGuard is commercialized in the US as a laboratory-developed test and was granted a final Medicare payment determination of $1,938.01, effective January 1.

• EsoCheck is commercialized as FDA 510(k)-cleared esophageal cell collection device.

• Price Action: PAVM shares are up 15.6% at $9.49 during the market session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Baxter's Norepinephrine Wins FDA Nod For Low Blood Pressure

• Stealth Bio Posts Encouraging Preclinical Data In Parkinson's Animal Studies

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.